Analyst initiated coverage on Ascentage Pharma
$AAPG
Biotechnology: Pharmaceutical Preparations
Health Care
Analyst initiated coverage of Ascentage Pharma with a rating of Overweight
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/24/2025 | Buy | Truist | |
| 11/10/2025 | $50.00 | Buy | BTIG Research |
| 11/5/2025 | $48.00 | Overweight | Piper Sandler |
| 3/27/2025 | Overweight | Analyst |
Largest prospective clinical trial to-date in a rare subtype of GIST ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ:AAPG, HKEX: 6855)), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced the publication of clinical and translational data from a Phase Ib study (NCT03594422) on the Company's novel drug, olverembatinib (HQP1351), in patients with gastrointestinal stromal tumors (GIST), by the renowned scientific journal Signal Transduction and Targeted Therapy (Im
ROCKVILLE, Md. and SUZHOU, China, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)) ("Ascentage Pharma" or the "Company"), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company's management is scheduled to participate in three upcoming investor conferences in December 2025. Piper Sandler 37th Annual Healthcare Conference: Fireside chat at 9:00 am EST on December 2ndEvercore ISI HealthCONx Conference: Fireside chat at 3:50 pm EST on December 3rdCiti 2025 Global Hea
ROCKVILLE, Md. and SUZHOU, China, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ:AAPG, HKEX: 6855)), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that the latest results from multiple clinical studies of its novel drug, olverembatinib (HQP1351), have been selected for presentations at the 67th American Society of Hematology (ASH) Annual Meeting, marking the eighth consecutive year in which clinical data on olverembatinib have been selected by ASH for the Annual Meeting. This year, multiple
6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
Truist initiated coverage of Ascentage Pharma with a rating of Buy
BTIG Research initiated coverage of Ascentage Pharma with a rating of Buy and set a new price target of $50.00
Piper Sandler initiated coverage of Ascentage Pharma with a rating of Overweight and set a new price target of $48.00
ROCKVILLE, Md. and SUZHOU, China, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)) ("Ascentage Pharma" or the "Company"), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced today that it will release its six months 2025 unaudited interim results and provide business updates at 7:00 pm Eastern Daylight Time (EDT) on August 20, 2025 / 7:00 am Hong Kong Time (HKT) on August 21, 2025. Analysts and investors are invited to join the investor webcast with Q&A, conducted by the Company's management team. Ascentage Pharma will host a Chinese (Mandarin) language investor webcast at 9:00 pm EDT on Aug
ROCKVILLE, Md. and SUZHOU, China, March 12, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ:AAPG, HKEX: 6855)), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that it will release full year 2024 financial results, and provide an update on recent developments on March 27, 2025 at 7:00 am Eastern Daylight Time (EDT) / 7:00 pm Hong Kong Time (HKT). Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by the Ascentage management team. The English conference call and webcast will be he